Samsung Biologics named to Dow Jones Best-in-Class Index for 5th year, highlighting strong ESG progress.

Samsung Biologics has been included in the Dow Jones Best-in-Class World Index for the fifth consecutive year, reflecting its strong commitment to environmental, social, and governance (ESG) practices. The recognition is based on a rigorous global sustainability assessment and highlights the company's improvements in supply chain management, environmental care, and workplace safety. This continued inclusion underscores Samsung Biologics' proactive approach to sustainable growth and transparent governance, supported by recent accolades like an EcoVadis Platinum rating and a sustainability award. The company plans to keep advancing its ESG initiatives while expanding its global manufacturing capacity to support future therapies.